EU Authorizes Novavax COVID-19 Vaccine
The vaccine is now fully authorized for use as a primary series in individuals aged 12 and older and as a booster dose in adults aged 18 and older for the prevention of COVID-19.
The vaccine is now fully authorized for use as a primary series in individuals aged 12 and older and as a booster dose in adults aged 18 and older for the prevention of COVID-19.
Novavax Inc's COVID-19 vaccine demonstrated 80% efficacy overall in a study of over 2,000 pediatric patients when the Delta variant was the predominant circulating strain in the US.
Novavax Inc's COVID-19 vaccine NVX-CoV2373 demonstrated 90.4% overall efficacy against SARS-CoV-2 infection, and 100% protection against moderate and severe disease, according to a Phase 3 PREVENT-19 clinical trial.